GS010 Improves Vision in Patients with Mitochondrial Disease That Impacted Their Sight, Trial Shows
GenSight Biologics’ GS010 gene therapy restored some of the vision in Leber’s Hereditary Optic Neuropathy (LHON) patients whose sight had deteriorated, according to a Phase 1/2 clinical trial. The findings were from a 96-week trial (NCT02064569) assessing the long-term effectiveness and safety of GS010. LHON is a rare mitochondrial disease…